Comprehensive Analysis of the Glioblastoma Multiforme (GBM) Treatment Market 2025-2034: Growth Rates, Trends, and Future Opportunities
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What fueled the previous growth in the glioblastoma multiforme (gbm) treatment market?
In recent times, the market size for glioblastoma multiforme (GBM) treatment has seen a swift expansion. The market which is estimated to be at $2.48 billion in 2024 will rise to $2.74 billion in 2025, showcasing a compound annual growth rate (CAGR) of 10.2%. Factors such as a boost in occurrence and prevalence, progress in diagnostic methods, financial aid for clinical trials and research, mutually beneficial collaborations and partnerships, along with an enhanced comprehension of tumor biology have all contributed towards growth during the previous period.
What will be the glioblastoma multiforme (gbm) treatment market size in the future?
Get your glioblastoma multiforme (gbm) treatment market report here!
What main drivers are fueling expansion in the glioblastoma multiforme (gbm) treatment market?
The escalating incidence rate of brain dysfunctions is predicted to bolster the expansion of the Glioblastoma Multiforme (GBM) treatment market in the future. Brain dysfunctions encompass irregular operations of the brain, nerves present in the human body, and spinal cord. The rising incidence rate of such disorders, including Glioblastoma Multiforme (GBM), can be attributed to multiple factors like aging demographics, weakened immune systems, the overdiagnosis phenomenon, ionizing radiation, air pollution, and more. These issues necessitate the treatment of brain dysfunctions for enhanced health and wellness. As mentioned in a study by the American Cancer Society, a US-based voluntary health alliance with a mission to eradicate cancer, around 25,050 malignant tumors related to brain or spinal cord cancer were identified in the US in 2022. Thus, the surging incidence of brain dysfunctions is fostering the growth of the Glioblastoma Multiforme (GBM) treatment market.
What key areas define the segmentation of the global glioblastoma multiforme (gbm) treatment market?
The glioblastoma multiforme (GBM) treatment market covered in this report is segmented –
1) By Treatment: Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy, Immunotherapy
2) By Drug Class: Temozolomide, Bevacizumab, Lomustine, Carmustine Wafers, Other Drug Classes
3) By Route Of Administration: Oral, Parenteral, Other Route Of Administrations
4) By End-Use: Hospitals, Clinics, Ambulatory Surgical Centers
Subsegments:
1) By Surgery: Tumor Resection, Biopsy Procedures
2) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Stereotactic Radiation Therapy
3) By Chemotherapy: Standard Chemotherapy, Combination Chemotherapy Regimens
4) By Targeted Therapy: EGFR Inhibitors, Other Targeted Agents
5) By Tumor Treating Field (TTF) Therapy: Device-Based TTF Treatment
6) By Immunotherapy: Checkpoint Inhibitors, Vaccine-Based Therapies
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8803&type=smp
Who are the dominant players expanding their reach in the glioblastoma multiforme (gbm) treatment market?
Major companies operating in the glioblastoma multiforme (GBM) treatment market include Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca PLC, Amgen Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Jazz Pharmaceuticals Inc., Sumitomo Dainippon Pharma Oncology Inc., Varian Medical Systems Inc., Amneal Pharmaceuticals Inc., Elekta AB, ANI Pharmaceuticals Inc., Accord Healthcare Limited, The Eckert & Ziegler Group, Loxo Oncology Inc., Karyopharm Therapeutics Inc., Celon Laboratories Pvt. Ltd., EnGeneIC Ltd., Zydus Pharmaceuticals Inc., Genenta Science S.r.l., Cantex Pharmaceuticals Inc., Vascular Biogenics Ltd., Seelos Therapeutics Inc, Angiochem Inc., Diffusion Pharmaceuticals Inc.
How are evolving market trends shaping glioblastoma multiforme (gbm) treatment Strategies?
Leading corporations in the glioblastoma multiforme (GBM) therapy industry encompass Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca PLC, Amgen Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Jazz Pharmaceuticals Inc., Sumitomo Dainippon Pharma Oncology Inc., Varian Medical Systems Inc., Amneal Pharmaceuticals Inc., Elekta AB, ANI Pharmaceuticals Inc., Accord Healthcare Limited, The Eckert & Ziegler Group, Loxo Oncology Inc., Karyopharm Therapeutics Inc., Celon Laboratories Pvt. Ltd., EnGeneIC Ltd., Zydus Pharmaceuticals Inc., Genenta Science S.r.l., Cantex Pharmaceuticals Inc., Vascular Biogenics Ltd., Seelos Therapeutics Inc, Angiochem Inc., and Diffusion Pharmaceuticals Inc.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8803
Which regions are emerging as leaders in the glioblastoma multiforme (gbm) treatment market?
North America was the largest region in the glioblastoma multiforme (GBM) treatment market share in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glioblastoma multiforme (gbm) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Neurology Devices Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/neurology-devices-global-market-report
Neurology Devices Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/neurology-devices-global-market-report
Neuroprosthetics Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/neuroprosthetics-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
